Top-Rated StocksTop-RatedNASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis $55.27 -0.42 (-0.75%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Protagonist Therapeutics Stock (NASDAQ:PTGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PTGX alerts:Sign Up Key Stats Today's Range$55.26▼$57.2450-Day Range$42.01▼$56.3752-Week Range$32.50▼$60.60Volume912,326 shsAverage Volume891,584 shsMarket Capitalization$3.43 billionP/E Ratio74.25Dividend YieldN/APrice Target$66.10Consensus RatingBuy Company OverviewProtagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Read More… Protagonist Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScorePTGX MarketRank™: Protagonist Therapeutics scored higher than 21% of companies evaluated by MarketBeat, and ranked 858th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Protagonist Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $2.43 to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is 73.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is 73.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.46.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 4.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Protagonist Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.03% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 13.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.03% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 13.44%, indicating that investor sentiment is decreasing significantly. News and Social Media1.5 / 5News Sentiment0.75 News SentimentProtagonist Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Protagonist Therapeutics this week, compared to 6 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $651,076.00 in company stock.Percentage Held by InsidersOnly 4.90% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Stock News HeadlinesArturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) StockJune 12, 2025 | insidertrades.comProtagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity5 hours ago | usatoday.comHow high will gold surge? Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and declared a historic event would send the yellow metal to $3,150. People laughed at him at the time, but he was off by just two days. Now, Sean has a shocking new prediction for gold … and reveals a little-known way to get ahead of this bull market.June 30 at 2:00 AM | Weiss Ratings (Ad)Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?5 hours ago | msn.comPTGX Protagonist Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comProtagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia VeraJune 24, 2025 | msn.comProtagonist Therapeutics’ SWOT analysis: biotech stock poised for growthJune 20, 2025 | investing.comCiti Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs OpportunityJune 20, 2025 | msn.comSee More Headlines PTGX Stock Analysis - Frequently Asked Questions How have PTGX shares performed this year? Protagonist Therapeutics' stock was trading at $38.60 on January 1st, 2025. Since then, PTGX stock has increased by 43.2% and is now trading at $55.27. View the best growth stocks for 2025 here. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) posted its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.31. The business had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a net margin of 27.04% and a trailing twelve-month return on equity of 9.22%. When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY). Company Calendar Last Earnings5/06/2025Today6/30/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTGX CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$66.10 High Stock Price Target$80.00 Low Stock Price Target$38.00 Potential Upside/Downside+19.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.75 Trailing P/E Ratio73.69 Forward P/E Ratio22.74 P/E GrowthN/ANet Income$275.19 million Net Margins27.04% Pretax Margin27.47% Return on Equity9.22% Return on Assets8.31% Debt Debt-to-Equity RatioN/A Current Ratio17.25 Quick Ratio17.26 Sales & Book Value Annual Sales$434.43 million Price / Sales7.89 Cash Flow$4.48 per share Price / Cash Flow12.33 Book Value$11.33 per share Price / Book4.88Miscellaneous Outstanding Shares61,980,000Free Float58,945,000Market Cap$3.43 billion OptionableOptionable Beta2.25 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:PTGX) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.